Form 8-K - Current report:
SEC Accession No. 0001104659-25-049411
Filing Date
2025-05-15
Accepted
2025-05-15 16:05:46
Documents
15
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2515284d1_8k.htm   iXBRL 8-K 24303
2 EXHIBIT 99.1 tm2515284d1_ex99-1.htm EX-99.1 74688
6 GRAPHIC tm251528d1_ex99-1img001.jpg GRAPHIC 5084
  Complete submission text file 0001104659-25-049411.txt   291309

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20250515.xsd EX-101.SCH 3047
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20250515_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20250515_pre.xml EX-101.PRE 22380
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2515284d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 25952714
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)